Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Colville-Nash

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Presse Medicale (Paris, France : 1983)|January 9, 2003
[Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model]P R Colville-Nash
Journal of Molecular Medicine (Berlin, Germany)|June 27, 2000
New insights into the role of COX 2 in inflammationD W Gilroy, P R Colville-Nash
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 5, 2001
Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammationP R Colville-Nash, D W Gilroy
Prostaglandins & Other Lipid Mediators|August 11, 2000
COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?P R Colville-Nash, D W Gilroy
Drug News & Perspectives|July 25, 2003
Cyclooxygenase enzymes as targets for therapeutic intervention in inflammationP R Colville-Nash, D W Gilroy
Annals of the Rheumatic Diseases|July 1, 1992
Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implicationsP R Colville-Nash, D L Scott
Molecular Medicine Today|January 1, 1997
Growth factors in angiogenesis: current interest and therapeutic potentialP R Colville-Nash, D A Willoughby
Nature Medicine|February 2, 2000
Cyclopentenone prostaglandins-new allies in the war on inflammationD A Willoughby, A R Moore, P R Colville-Nash
Journal of Lipid Mediators|March 1, 1993
Inflammation, prostaglandins, and loss of functionD A Willoughby, P R Colville-Nash, M P Seed
Agents and Actions|January 1, 1993
The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradationP R Colville-Nash, M el-Ghazaly, D A Willoughby
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Presse Medicale (Paris, France : 1983)|January 9, 2003
[Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model]P R Colville-Nash
Journal of Molecular Medicine (Berlin, Germany)|June 27, 2000
New insights into the role of COX 2 in inflammationD W Gilroy, P R Colville-Nash
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 5, 2001
Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammationP R Colville-Nash, D W Gilroy
Prostaglandins & Other Lipid Mediators|August 11, 2000
COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?P R Colville-Nash, D W Gilroy
Drug News & Perspectives|July 25, 2003
Cyclooxygenase enzymes as targets for therapeutic intervention in inflammationP R Colville-Nash, D W Gilroy
Annals of the Rheumatic Diseases|July 1, 1992
Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implicationsP R Colville-Nash, D L Scott
Molecular Medicine Today|January 1, 1997
Growth factors in angiogenesis: current interest and therapeutic potentialP R Colville-Nash, D A Willoughby
Nature Medicine|February 2, 2000
Cyclopentenone prostaglandins-new allies in the war on inflammationD A Willoughby, A R Moore, P R Colville-Nash
Journal of Lipid Mediators|March 1, 1993
Inflammation, prostaglandins, and loss of functionD A Willoughby, P R Colville-Nash, M P Seed
Agents and Actions|January 1, 1993
The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradationP R Colville-Nash, M el-Ghazaly, D A Willoughby
Pageof 3